跳至主要内容
临床试验/NCT00603343
NCT00603343已完成3 期

Treatment With Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence: Results of a Randomized Placebo-Controlled Phase III Clinical Trial

APOGEPHA Arzneimittel GmbH0 个研究点目标入组 303 人开始时间: 2004年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
303
主要终点
voiding frequency

研究概览

简要总结

The study was conducted between 2004 and 2006 to prove efficacy and tolerability of the antimuscarinic propiverine compared to placebo in children suffering from non-neurogenic overactive bladder and urinary incontinence.

详细描述

This clinical trial showed superior efficacy of propiverine over placebo and convincing tolerability for the treatment of children suffering from OAB and urinary incontinence.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
5 Years 至 10 Years(Child)
性别
All
接受健康志愿者

入选标准

  • voiding frequency 8 or above per day
  • at least one incontinence episode per day
  • age between 5-10 years
  • body weight between 17 and 45 kg

排除标准

  • normal age expected bladder capacity
  • PVR more than 10 ml
  • dysfunctional voiding
  • neurogenic disorders
  • UTI, constipation

研究组 & 干预措施

1

Active Comparator

干预措施: Mictonetten 5 mg, coated tablet (Drug)

2

Placebo Comparator

干预措施: placebo (Drug)

结局指标

主要结局

voiding frequency

时间窗: before therapy and at end of therapy

次要结局

  • voided volume(before and at end of treatment)
  • incontinence episodes per day(before and at end of therapy)
  • safety parameters: acute urinary retention, post void residual urine, urinalysis, ECG, blood pressure, pulse rate(before and at end of treatment)

研究者

申办方类型
Industry

相似试验

进行中(未招募)
不适用
Propiverine hydrochloride in children suffering from overactive bladder and urinary incontinenceA randomised, double-blind, placebo-controlled, parallel grouped, multicentre clinical trialchildren suffering from overactive bladder and urinary incontinenceMedDRA version: 8.0Level: lltClassification code 10059617
EUCTR2004-001243-30-SEAPOGEPHA Arzneimittel GmbH200
进行中(未招募)
1 期
Propiverine hydrochloride in children suffering from overactive bladder and urinary incontinence. A randomised, double-blind, placebo-controlled, parallel grouped multicentre clinical trial.children suffering from overactive bladder and urinary incontinence
EUCTR2004-001243-30-SKApogepha Arzneimittel GmbH490
尚未招募
3 期
Propiverine hydrochloride in children suffering from overactive bladder and urinary incontinence. A randomised, double-blind, placebo-controlled, parallel grouped multicentre clinical trialdetrusorinstabilityOveractive bladderurgency10004994
NL-OMON30181APOGEPHA Arzneimittel GmbH8
进行中(未招募)
不适用
Propiverine hydrochloride in children suffering from overactive bladder and urinary incontinence. A randomised, double-blind, placebo-controlled, parallel grouped multicentre clinical trial.children suffering from overactive bladder and urinary incontinence
EUCTR2004-001243-30-CZApogepha Arzneimittel GmbH490
进行中(未招募)
不适用
Propiverine hydrochloride in children suffering from overactive bladder and urinary incontinenceA randomised, double-blind, placebo-controlled, parallel grouped, multicentre clinical trialOveractive bladder with incontinence episodesMedDRA version: 8.0Level: LLTClassification code 10059617
EUCTR2004-001243-30-ATAPOGEPHA Arzneimittel GmbH200